184 related articles for article (PubMed ID: 17567883)
21. Stimulated GH levels during the transition phase in Prader-Willi syndrome.
Grugni G; Marzullo P; Delvecchio M; Iughetti L; Licenziati MR; Osimani S; Ragusa L; Salvatoni A; Sartorio A; Stagi S; Crinò A;
J Endocrinol Invest; 2021 Jul; 44(7):1465-1474. PubMed ID: 33095904
[TBL] [Abstract][Full Text] [Related]
22. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial.
Kuppens RJ; Mahabier EF; Bakker NE; Siemensma EP; Donze SH; Hokken-Koelega AC
Orphanet J Rare Dis; 2016 Nov; 11(1):153. PubMed ID: 27852283
[TBL] [Abstract][Full Text] [Related]
23. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
[TBL] [Abstract][Full Text] [Related]
24. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
[TBL] [Abstract][Full Text] [Related]
25. Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome.
Nyunt O; Harris M; Hughes I; Huynh T; Davies PS; Cotterill AM
J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1151-8. PubMed ID: 20333875
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and treatment of GH deficiency in Prader-Willi syndrome.
Grugni G; Marzullo P
Best Pract Res Clin Endocrinol Metab; 2016 Dec; 30(6):785-794. PubMed ID: 27974191
[TBL] [Abstract][Full Text] [Related]
27. Growth hormone treatment and bone mineral density in pediatric patients with Prader-Willi syndrome.
Oto Y; Murakami N; Inoue T; Matsubara K; Saima S; Ogata H; Ihara H; Nagai T; Matsubara T
J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1181-1184. PubMed ID: 34162033
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
Lindgren AC; Lindberg A
Horm Res; 2008; 70(3):182-7. PubMed ID: 18663319
[TBL] [Abstract][Full Text] [Related]
29. Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment.
Cadoudal T; Buléon M; Sengenès C; Diene G; Desneulin F; Molinas C; Eddiry S; Conte-Auriol F; Daviaud D; Martin PG; Bouloumié A; Salles JP; Tauber M; Valet P
Int J Obes (Lond); 2014 Sep; 38(9):1234-40. PubMed ID: 24406482
[TBL] [Abstract][Full Text] [Related]
30. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment.
Festen DA; Visser TJ; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2007 Sep; 67(3):449-56. PubMed ID: 17716335
[TBL] [Abstract][Full Text] [Related]
31. Circulating insulin-like growth factor 1 levels are reduced in very young children with Prader-Willi syndrome independent of anthropometric parameters and nutritional status.
Koizumi M; Konishi A; Etani Y; Ida S; Kawai M
Clin Endocrinol (Oxf); 2022 Mar; 96(3):346-352. PubMed ID: 34750859
[TBL] [Abstract][Full Text] [Related]
32. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
Carrel AL; Myers SE; Whitman BY; Allen DB
J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
[TBL] [Abstract][Full Text] [Related]
33. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
Fillion M; Deal C; Van Vliet G
J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
[TBL] [Abstract][Full Text] [Related]
34. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
Allen DB; Carrel AL
J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
[TBL] [Abstract][Full Text] [Related]
35. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Duivenvoorden HJ; Otten BJ; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Apr; 94(4):1274-80. PubMed ID: 19158197
[TBL] [Abstract][Full Text] [Related]
36. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
[TBL] [Abstract][Full Text] [Related]
37. Cognitive functioning in children with Prader-Willi syndrome during 8 years of growth hormone treatment.
Donze SH; Damen L; Mahabier EF; Hokken-Koelega ACS
Eur J Endocrinol; 2020 Apr; 182(4):405-411. PubMed ID: 31961800
[TBL] [Abstract][Full Text] [Related]
38. Is growth hormone treatment in children associated with weight gain?--longitudinal analysis of KIGS data.
Reinehr T; Lindberg A; Koltowska-Häggström M; Ranke M
Clin Endocrinol (Oxf); 2014 Nov; 81(5):721-6. PubMed ID: 24750131
[TBL] [Abstract][Full Text] [Related]
39. What is the value of growth hormone therapy in Prader Willi syndrome?
Bridges N
Arch Dis Child; 2014 Feb; 99(2):166-70. PubMed ID: 24162007
[TBL] [Abstract][Full Text] [Related]
40. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
